Figure 6.
Targeted therapy to PI3K pathway ameliorated the abnormal B cell phenotypes in APDS patients. The peripheral blood from HC (n=8), the patients who had not been treated (n=3) and those who received targeted therapy (n=5) was analyzed for the percentages of different B cells subsets by flow cytometry and serum IgM by ELISA. P values were calculated by one-tailed unpaired t-test.